E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Neonates and Infants up to 3 months including with prenatally or postnatally confirmed urea cycle disorder with below listed deficiency and children aged > 3 months up to 5 years including with confirmed urea cycle disorder and unstable metabolism with deficiency of either:
- Carbamyl-phosphate Synthetase I Deficiency (CPS1D)
- Ornithine Transcarbamylase Deficiency (OTCD)
- Argininosuccinate Synthetase Deficiency (ASSD/Citrullinaemia)
can be included.
|
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10052450 |
E.1.2 | Term | Ornithine transcarbamoylase deficiency |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10058298 |
E.1.2 | Term | Argininosuccinate synthetase deficiency |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10058297 |
E.1.2 | Term | Carbamoyl phosphate synthetase deficiency |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Main objective of the trial is to investigate the safety and efficacy of multiple applications of liver cell suspension in neonates, infants and children with the above defined subset of urea cycle disorders (UCD).
Primary variables:
• Safety of the application of liver cells as measured by oxygen saturation, portal blood pressure and flow during the infusion
• Safety of the placement of an application catheter to the portal vein
• Safety of the placement of an application catheter to the portal vein by evaluation of all adverse events judged to be related to the catheter placement
|
|
E.2.2 | Secondary objectives of the trial |
Efficacy variables
•Change in respective enzyme activity in explanted liver after OLT compared to enzyme activity in liver prior first cell application
•Changes in 13C urea formation from baseline to 2/4 months after HHLivC infusion, and if available up to month 24 after Final Visit in case further 13C-ureagenesis tests after HHLivC infusion
•Detection of donor cell material in samples from explanted liver taken after orthotopic liver transplantation compared with liver biopsy taken prior first liver cell application
•Number, duration and severity of metabolic crises (maximum ammonia concentration, duration of coma)
•Laboratory parameters: ammonia and amino acids in plasma and orotic acid in urine (except CPS1D)
•Growth and protein intake
•Nutritional status
•Use of ammonia scavenging drugs
•Time to death and survival 6 months after liver cell infusion
Safety variables
-Vital signs
-Lab Parameters to monitor safety of the procedures+immunosuppression
-AEs
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Neonates and Infants up to 3 months including with prenatally or postnatally confirmed urea cycle disorder with deficiency of either:
- Carbamyl-phosphate Synthetase I Deficiency (CPS1D)
- Ornithine Transcarbamylase Deficiency (OTCD)
- Argininosuccinate Synthetase Deficiency (ASSD/Citrullinaemia)
and children aged > 3 months up to 5 years including with confirmed urea cycle disorder and unstable metabolism with deficiency of either
- Carbamyl-phosphate Synthetase I Deficiency (CPSD)
- Ornithine Transcarbamylase Deficiency (OTCD)
- Argininosuccinate Synthetase Deficiency (Citrullinaemia)
can be included.
- Accessibility of the portal vein.
- Plasma ammonia level </= 250 µmol/l
- Written informed consent from parents or legal guardian(s).
|
|
E.4 | Principal exclusion criteria |
- Structural liver disease (cirrhosis, portal hypertension), or venoocclusive diseases,
- Portal vein thrombosis
- Body Weight less than/equal 3.5 kg
- Carrier of the human immuno-deficieny virus (HIV),
- Any other contraindication for immunosuppression,
- Presence of acute infection at the time of inclusion,
- Participation in other clinical trials or received experimental medication within last 30 days,
- Live vaccination planned during the course of the study
- Live vaccination within 4 weeks prior to beginning of study
- Allergic disposition against contrast medium used in study and/or antibiotics used in the manufacturing process,
- Required valproate therapy
- Severe coagulopathy or thrombocytopenia,
- Known diagnosis of hereditary thrombophilia (e.g. Factor V Leiden, Prothrombin 20210A variant) or parental history of hereditary thrombophilia and absence of thrombophilia testing in subject
- Cancer, severe systemic or chronic disease other than study indication (urea cycle deficiency).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary variable is:
- safety of the application of liver cells as measured by oxygen saturation, portal blood pressure and flow during the infusion
- safety of the placement of an application catheter to the portal vein
- safety of the placement of an application catheter to the portal vein by evaluation of all adverse events judged to be related to the catheter placement |
|
E.5.2 | Secondary end point(s) |
Secondary safety variables:
• Vital signs
• Laboratory Parameters III to V to monitor the safety of the procedures and the immunosuppression
• Adverse events
Secondary efficacy variables:
• Change in the respective enzyme activity in samples from the explanted liver taken after orthotopic liver transplantation compared to
the enzyme activity in the liver biopsy taken prior to the first liver cell
application
• Changes in 13C urea formation from baseline to 2 and 4 months (or earlier, if OLT is performed during listing period) after first infusion of HHLivC, and if available, up to month 24 (FUV 5) after the Final Visit in case further 13C-ureagenesis tests were performed after infusion of HHLivC.
• Detection of donor cell material in samples from the explanted liver taken after orthotopic liver transplantation compared with the liver biopsy taken prior to first liver cell application
• Number, duration and severity of metabolic crises (maximum ammonia concentration, duration of coma)
• Laboratory parameters I and II: ammonia and amino acids in plasma and orotic acid in urine (except CPS1D)
• Growth and protein intake
• Nutritional status
• Use of ammonia scavenging drugs
• Time to death and survival 6 months after liver cell infusion
Exploratory variable:
• Total urea and orotic acid (except CPS1D) in 12-hour urine
• Urea in serum |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Descriptive analysis:
After treatment of the 5th patient an interim analysis has been conducted and did not reveal any safety concerns (conducted in July 2010).
A second interim analysis was performed after the treatment of the 11th patient in Q4 2013.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as the database lock. This time point is when the last clinical data will be reported. The last visit of the last patient is not the end of the study, as the analysis of biopsies from explanted organ after OLT (if applicable) derived at this visit may require an extended period of time (samples frozen in liquid nitrogen, shipped to analytical laboratory, and there possibly analyzed in batches). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |